Emergent releases results from Phase 1a anthrax vaccine trial
The results of the trial demonstrated that BioThrax plus CPG 7909 generated antibody responses that were 6-fold higher than those generated by BioThrax alone (232µg/ml with BioThrax alone;
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.